Momenta Pharmaceuticals, Inc. (MNTA)
(Delayed Data from NSDQ)
$14.57 USD
+0.53 (3.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.58 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.57 USD
+0.53 (3.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $14.58 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Why Is Momenta (MNTA) Up 86.9% Since Last Earnings Report?
by Zacks Equity Research
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Immunovant Up on Positive Data From Myasthenia Gravis Study
by Zacks Equity Research
Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.
ETFs in Focus on Momenta Buyout Deal With JNJ
by Sweta Killa
A number of ETFs could be the best ways for investors to tap the opportunity arising from the Momenta buyout deal.
J&J to Buy Momenta for $6.5B to Boost Autoimmune Presence
by Zacks Equity Research
J&J (JNJ) offers to buy Momenta, which focuses on the development of novel drugs to treat rare, immune-mediated disorders.
Momenta Surges on Acquisition Deal With Johnson & Johnson
by Zacks Equity Research
Momenta (MNTA) soars on the announcement of being acquired by Johnson & Johnson for $6.5 billion.
Company News for Aug 20, 2020
by Zacks Equity Research
Companies In The News Are: MNTA, JNJ, TGT, REGN, GLPG, GILD.
S&P 500 Records a Fresh All-Time High
by Zacks Equity Research
S&P 500 Records a Fresh All-Time High.
Pre-Markets Mixed Following S&P 500's Fresh High, Strong Earnings
by Zacks Equity Research
Market participants enjoyed an astonishing 54.7% rally of the broad-market S&P 500 Index since its crash on Mar 23.
Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Momenta (MNTA) delivered earnings and revenue surprises of -14.29% and 13.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Top Ranked Momentum Stocks to Buy for July 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 6th.
The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals
Momenta (MNTA) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Momenta (MNTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
5 Top Momentum Stocks of June Amid Resurgence of Coronavirus
by Nalak Das
Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.
Momenta Pharmaceuticals, Inc. (MNTA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Momenta Pharmaceuticals, Inc. (MNTA).
Biotech Stock Roundup: REGN Begins Coronavirus Study, VRTX, BIIB Give Updates
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Momenta (MNTA) Up on Positive Data From Generalized MG Drug
by Zacks Equity Research
Momenta (MNTA) stock up on the announcement of positive data from a mid-stage study on nipocalimab for the indication of gMG.
Company News for Jun 16, 2020
by Zacks Equity Research
Companies in the news are: JKS, MNTA, CAI, CATM
Why Is Momenta (MNTA) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH